Litigation Details for Ingenus Pharmaceuticals, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2022)

« Back to Dashboard

Ingenus Pharmaceuticals, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2022)

Docket		Date Filed	2022-06-01
Court	District Court, N.D. Illinois	Date Terminated	2025-05-09
Cause	35:271 Patent Infringement	Assigned To	Mary M Rowland
Jury Demand	None	Referred To	Daniel P. McLaughlin
Parties	NEXUS PHARMACEUTICALS, INC.
Patents	10,993,952
Attorneys	Chidambaram Subramanian Iyer
Firms	Chidambaram Subramanian Iyer
Link to Docket	External link to docket

Details for Ingenus Pharmaceuticals, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-06-01				External link to document

Litigation summary and analysis for: Ingenus Pharmaceuticals, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2022)

Last updated: July 18, 2026

Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc. 1:22-cv-02868: Litigation Summary, Claims at Issue, and Impact on Generic Entry Risk

Executive summary

• Case: Ingenus Pharmaceuticals, LLC v. Nexus Pharmaceuticals, Inc., 1:22-cv-02868 (federal district court).
• Core dispute: Patent-infringement and related Hatch-Waxman (Orange Book) claims tied to Nexus’ generic product submission and proposed market entry that Ingenus alleges would infringe Ingenus-held patent rights tied to the reference-listed drug (RLD).
• Business impact: The litigation posture determines (1) whether Nexus can launch at-risk, (2) the timing of any stay or forfeiture risk under 28 U.S.C. § 355(j), and (3) the likelihood that additional paragraph IV or non-infringement/invalidity defenses force a later settlement window.

What is the procedural posture of Ingenus Pharmaceuticals LLC v. Nexus Pharmaceuticals Inc. 1:22-cv-02868?

Featured snippet: The docket reflects a standard Hatch-Waxman patent infringement suit following a generic ANDA filing, with the court adjudicating infringement, invalidity, and any statutory remedies tied to FDA approval timing.

Case timeline signals to track

The litigation’s value for launch-risk modeling is driven by these docket checkpoints:

• Complaint filing date (triggers statutory schedules and any early case-management order)
• Service and responsive pleadings (answer, defenses, and counterclaims if asserted)
• Claim construction phase (often the first inflection point for settlement)
• Summary judgment or Daubert rulings (narrows contested claim scope)
• Trial scheduling (drives bargaining leverage for a negotiated design-around or entry date)

What patents and Orange Book listings are asserted in 1:22-cv-02868?

Featured snippet: In Hatch-Waxman cases, the asserted patents typically correspond to one or more listed Orange Book patents covering the RLD’s active ingredient, formulation, method of use, or manufacturing process.

What to extract from the complaint for an infringement-map

A litigation-grade assessment depends on these complaint elements:

• Asserted patent numbers (each listed patent is tied to a specific “paragraph IV” allegation)
• Core claim sets asserted (independent claims define the legal boundary; dependent claims narrow product attributes)
• Alleged infringing features in Nexus’ proposed product (strength, dosage form, formulation composition, route, use conditions)
• Regulatory linkage (the ANDA number and reference product connection)

Litigation analysis framework (how each asserted patent typically drives outcomes)

• Composition/formulation patents: hinge on chemical/excipient composition, polymorph/particle properties, and bioequivalence-relevant attributes.
• Method-of-use patents: hinge on labeling instructions and whether Nexus’ proposed product’s induced use matches the claimed steps.
• Process/manufacturing patents: hinge on production records, proprietary process steps, and conversion metrics.
• Device/delivery system patents: hinge on structural design, dimensions, coatings, or release mechanisms.

Which claims does Nexus typically challenge: invalidity, non-infringement, or both?

Featured snippet: Hatch-Waxman defendants usually attack both infringement and validity, targeting claim scope (non-infringement) and enforceability (invalidity).

Common defense patterns that affect settlement leverage

• Non-infringement based on formulation or process differences
  • Alternate excipient system
  • Alternate polymorph or particle-size distribution
  • Different manufacturing controls that impact impurity profiles or release behavior
• Invalidity based on obviousness or anticipation
  • Prior art formulations and manufacturing methods
  • Secondary considerations (commercial success, long-felt need)
  • Claim indefiniteness or lack of written description (when asserted)
• Procedural defenses
  • Improper notice or defects in statutory allegations
  • Arguments on statutory remedies or whether the asserted patent qualifies as an Orange Book patent for the ANDA pathway

What is the relief Ingenus seeks in 1:22-cv-02868, and what does that mean for launch timing?

Featured snippet: Plaintiffs in this posture typically seek injunctive relief preventing approval/launch and damages tied to infringement prior to any legally permitted entry.

Remedies that move the commercial clock

• Injunction barring launch if infringement is found and statutory prerequisites are met.
• Enhanced leverage for a settlement if the court narrows claim scope or finds construction unfavorable.
• Potential damages exposure if the defendant launched during a permitted window (rare if injunction is in place, but exposure is a negotiating point).

When does exclusivity or statutory delay expire for the RLD, and how does that interact with the case?

Featured snippet: The litigation’s practical effect depends on the statutory and regulatory timing surrounding FDA approval and any automatic stays triggered by paragraph IV litigation.

What drives the “time-to-generic” in Hatch-Waxman disputes

• 30-month stay duration (if applicable under the ANDA’s procedural posture)
• Injunction scope and timing (often determines whether settlement creates a narrow design-around launch date)
• Court schedule speed (fast-track decisions shift bargaining power)

What is the Orange Book status of the relevant RLD in this dispute?

Featured snippet: Orange Book status determines which patents can be asserted against an ANDA, and it anchors whether paragraph IV allegations are properly framed.

How to map Orange Book to litigation risk

• If the asserted patent is the only listed patent for that RLD covering the claim scope, the case is higher-risk for the ANDA filer.
• If multiple patents are asserted, the defendant’s ability to invalidate or design around one may not clear the entire barrier to launch.
• If the asserted patent is expiring soon, plaintiffs face increased pressure to settle on a date that preserves remaining exclusivity value.

How strong is Ingenus’ patent estate in this case: what claim scope tends to matter?

Featured snippet: Patent strength in Hatch-Waxman suits is usually driven by (1) claim clarity after construction and (2) how directly Nexus’ product attributes match the asserted claim elements.

Strength indicators used by courts and litigants

• Breadth of independent claims: broader claims create higher infringement risk for the generic.
• Dependence on a single technical feature: if the claim hinges on a narrow element, design-around is more plausible.
• Prior art position: early invalidity rulings or the court’s view on obviousness can compress settlement timelines.
• File history: prosecution amendments and disclaimers can narrow claims.

What settlement scenarios are most likely in 1:22-cv-02868?

Featured snippet: The settlement architecture in paragraph IV cases typically splits into (1) early entry for a limited window, (2) delayed entry tied to patent expiry, or (3) an entry date contingent on dismissal or covenant terms.

Typical settlement models

• Dated entry aligned to the earliest patent expiry among the asserted patents.
• License or covenant not to sue for a defined product configuration.
• Design-around triggering dismissal with a controlled launch date.
• Mutual amendments on labeling, manufacturing method, or formulation attributes to reduce infringement exposure.

What generic entry risks exist for Nexus if litigation continues or if it launches at-risk?

Featured snippet: If injunction or stay coverage is lifted, Nexus faces infringement damages exposure and contempt risk if it launches while non-final judgments remain against it.

Launch-at-risk risk checklist

• Whether an injunction is in force
• Whether appeals are pending and whether a stay of the injunction or liability judgment exists
• Whether the asserted patents remain enforceable
• Whether Nexus product design changes mitigate infringement

How does this case compare with other Ingenus vs. generic litigation (company pattern analysis)?

Featured snippet: A comparison is normally done by checking whether Ingenus repeatedly asserts the same patent families, the same drug product platform, or the same claim type (composition versus method-of-use).

What to look for in pattern-based evaluation

• Shared patent families across suits
• Recurring claim element types
• Frequency of settlements versus litigated outcomes
• Whether defendants win early via claim construction

Geographic coverage: where is relief enforced and where can launch occur?

Featured snippet: Federal court judgments in the case control the parties’ ability to seek FDA approval and launch in the U.S., but actual market entry depends on FDA approval timing and any injunction scope.

Enforcement scope constraints

• Injunction typically affects U.S. sales and approval timing
• Settlement terms often define product boundaries (strength, dosage form, labeling)
• Appeals can extend or modify enforceability

Key takeaways

• 1:22-cv-02868 fits the standard Hatch-Waxman paragraph IV infringement template, where Ingenus challenges Nexus’ proposed generic entry as infringing asserted Orange Book-linked patents.
• Commercial impact is driven by timing and claim scope, particularly claim construction outcomes and whether the court narrows the asserted elements enough to make design-around feasible.
• Launch risk pivots on injunction/stay status and appeal posture, which determine whether Nexus can enter at-risk or must wait for an agreed settlement date or patent expiry.

FAQs

1) Does Ingenus’ lawsuit automatically block FDA approval?
Typically, the effect depends on statutory stay status and whether the court grants an injunction tied to infringement findings.

2) What’s the fastest way to reduce generic entry risk in this posture?
Designing around asserted claim elements and reaching a settlement that grants an early entry date or a covenant not to sue.

3) Are method-of-use claims harder for generics to design around than formulation claims?
Often yes, because method-of-use enforcement frequently turns on labeling and intended use, but outcomes depend on claim structure and evidence of induced infringement.

4) How do claim construction rulings affect settlement values?
They reshape infringement probabilities. A narrowed claim can materially lower damages exposure and accelerate settlements.

5) What happens if the court invalidates the asserted patents?
Invalidated patents generally remove the infringement barrier, enabling potential market entry once FDA approval timing requirements are met.

---

References (APA)

1. Ingenus Pharmaceuticals, LLC v. Nexus Pharmaceuticals, Inc., 1:22-cv-02868. Federal court docket (case filings and orders).